Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

BICO Group Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

BICO Group wird ein Gewinn- und Umsatzwachstum von 161.9% bzw. 10.4% pro Jahr prognostiziert, während der Gewinn pro Aktie um 161.9% pro Jahr wachsen soll.

Wichtige Informationen

152.7%

Wachstumsrate der Gewinne

152.7%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	17.0%
Wachstumsrate der Einnahmen	8.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	10 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

OTCPK:CLLK.F - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	2,777	-16	N/A	N/A	1
12/31/2024	2,428	-75	N/A	N/A	1
3/31/2024	2,426	-1,649	-98	101	N/A
12/31/2023	2,405	-1,697	-113	178	N/A
9/30/2023	2,273	-1,196	-435	-53	N/A
6/30/2023	2,277	-1,059	-526	-72	N/A
3/31/2023	2,297	-117	-643	-140	N/A
12/31/2022	2,327	-85	-799	-269	N/A
9/30/2022	2,278	41	-817	-313	N/A
6/30/2022	1,995	-130	-872	-457	N/A
3/31/2022	1,743	-224	-816	-462	N/A
12/31/2021	1,378	-228	-676	-409	N/A
9/30/2021	993	-188	-529	-321	N/A
6/30/2021	744	-96	-328	-150	N/A
3/31/2021	460	-50	-156	-34	N/A
12/31/2020	369	-36	-160	-59	N/A
8/31/2020	236	-62	-154	-72	N/A
5/31/2020	213	-49	-146	-70	N/A
2/29/2020	197	-24	-115	-53	N/A
11/30/2019	173	-5	-73	-31	N/A
8/31/2019	135	1	-52	-16	N/A
5/31/2019	118	3	-59	-16	N/A
2/28/2019	97	4	-38	-2	N/A
11/30/2018	76	2	-34	-12	N/A
8/31/2018	61	1	-31	-12	N/A
5/31/2018	45	1	-11	-6	N/A
2/28/2018	34	-2	N/A	-7	N/A
11/30/2017	27	-2	N/A	-8	N/A
8/31/2017	20	-1	N/A	-1	N/A
8/31/2016	6	-1	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CLLK.F wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CLLK.F wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CLLK.F wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CLLK.FDie Einnahmen des Unternehmens (8.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.5% pro Jahr).

Hohe Wachstumseinnahmen: CLLK.FDie Einnahmen des Unternehmens (10.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CLLK.F in 3 Jahren voraussichtlich hoch sein wird

BICO Group Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of Directors

BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024

BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of Directors

BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

BICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024

BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HR

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024

BICO Group AB (publ) Announces Chief Executive Officer Changes

Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million.

BICO Group AB (publ) Elects Gerry Mackay to Its Board of Directors

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023

BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFO

BICO Group AB (publ) to Report Q1, 2023 Results on May 04, 2023

BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023

BICO Group Announces Appointment of Nomination Committee 2023

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2023

BICO Group Adds Åsa Hillsten as SVP and Head of IR

BICO Group AB (publ) (OM : BICO) acquired Allegro 3D for $11 million.

BICO (publ) Appoints Mikael Engblom as Interim CFO

BICO Group AB (Publ) Announces Board Appointments

BICO Reaches Beneficial and Sustainable Solution with Organovo

DISPENDIX, A BICO Company, Announces That the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

BICO Group AB (publ) (OM:BICO) agreed to acquire Biosero Llc.

BICO Group AB (publ) (OM:BICO) acquired all outstanding shares in Advanced BioMatrix, Inc. for $18 million.

CELLINK Receives Patent for Robotic Systems for Personalized and Automated Aesthetic Medical Procedures

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Discover Echo Inc.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Nanoscribe GmbH for approximately €37 million.

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for €34 million.

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire MatTek Corporation for $68 million.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Ginolis Ltd from Verso Fund II of Verso Capital Oy, Finnvera plc and Innovestor Ventures for €65.7 million.

Cellink AB (publ) to Report Fiscal Year 2021 Results on Mar 16, 2022

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Ginolis Ltd for €70 million.

Cellink AB (publ) Announces Distribution Agreement Including New Products for Single-Cell RNA Sequencing and NGS Library Preparation

Cellink Announces Third Year Extension of Collaboration with A Global Biopharmaceutical Company for Drug Discovery

Cellink and Phasefocus Announces a Partnership to Bring Livecyte High Content Live Cell Imager to a Wider Audience

Cellink AB (publ) Elects Aristotelis Nastos as Member of the Board of Directors

CELLINK and Atelerix Team Up to Enable the Shipping At Room Temperature of Fragile 3D Bioprinted Constructs by the World's Bioprinting Community

CELLINK to Help Develop 3D Bioprinted Personalised Scaffolds for Tissue Regeneration of Ankle Joint S as Part of the Triankle Project

Cellink AB (publ) to Report Second Half, 2020 Results on Oct 22, 2020

Cellink AB (Publ) Announces Leaving Board of Directors for an Operational Role as Business Area Manager for the Bioprinting Business Unit

Cellink AB (publ) (OM:CLNK B) completed the acquisition of SCIENION AG from NRW.Bank Venture Fonds, L.P., managed by NRW.Bank, Investment Arm and other shareholders.

Cellink AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 945.99632 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken